Press Release Description

Improved Cancer Screening Rates Worldwide to Boost the Bladder Cancer Industry

A recent research report by MarkNtel Advisors cites that the Global Bladder Cancer Market is set to register around 4.6% CAGR during 2022-27, mainly due to the rising aging population and the growing prevalence of bladder cancer, especially among those aged above 50. It, in turn, is leading to increasing screening rates, diagnoses, & therapies for bladder cancer treatment worldwide and driving the global market.

Besides, rapid developments in medical science, especially in the oncology sector, are demonstrating various drug discoveries in multiple cancer treatments, including bladder cancer. As a result, governments of different countries worldwide are increasing the expenditure on the healthcare sector to boost the research & development initiatives while laying out favorable policies for the clinical trials of new medications. Hence, the bladder cancer market is experiencing a steady rise in its growth and generating lucrative opportunities for the leading players, further states the research report, “Global Bladder Cancer Market Analysis, 2022.”

Chemotherapy to Remain the Major Growth Contributor to the Global Bladder Cancer Market

Chemotherapy is by far the first standard treatment for bladder cancer patients. As more and more people are becoming aware of its effectiveness & higher OS (overall success) rates, it is set to dominate the Global Bladder Cancer Market with the largest share during 2022-27.

Moreover, as per the patient's health condition, oncologists might perform chemotherapy combined with other treatments like surgery, immunotherapy, radiation therapy, or targeted therapy to enhance its overall effectiveness. Hence, its ability to be combined with other therapeutics, which shows better patient outcomes, is another crucial aspect propelling the demand for chemotherapy drugs and, in turn, fueling the overall market growth.

With Massive Healthcare Expenditure & Active Participation of Biopharma Companies, North America Dominates the Market

North America is home to the best & biggest biotech & pharma companies that are actively participating in developing novel drugs for cancer treatment, including bladder cancer. Moreover, governments, especially the US & Canada, are substantially investing in the healthcare infrastructure and laying out favorable norms for biopharma firms to conduct clinical trials of new medications for bladder cancer treatment.

Besides, the increasing construction of hospitals, cancer research centers & institutes, specialty centers, etc., is leading to the surging requirements for more advanced & effective diagnosis equipment & drugs to treat patients with bladder cancer. Hence, these aspects indicate lucrative opportunities for the Bladder Cancer Market in North America over the forecast years.

Competitive Landscape

The top companies operating in the Global Bladder Cancer Market include AstraZeneca PLC, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Novartis International AG, Pfizer Inc., and Sanofi.

Key Questions Answered in the Research Report

  1. What are the current & future trends in the Global Bladder Cancer Market?
  2. How has the industry been evolving in terms of geography & product adoption?
  3. How has the competition been shaping across various regions, followed by their comparative factorial indexing?
  4. What are the key growth drivers & challenges for the Global Bladder Cancer Market?
  5. What are the customer orientation, purchase behavior, & expectations from the leading players in the Global Bladder Cancer Market?

Market Segmentation:

  1. By Diagnosis (Cystoscopy, Urine Tests, Imaging, Biopsy)
  2. By Cancer Type (Urothelial Carcinoma, Squamous Cell, Carcinoma, Adenocarcinoma)
  3. By Treatment (Surgery, Chemotherapy (Cisplatin, Gemcitabine, Fluorouracil (5-FU), Mitomycin, Others (Doxorubicin, etc.)), Immunotherapy (Atezolizumab (Tecentriq), Avelumab (Bavencio), Nivolumab (Opdivo), Pembrolizumab (Keytruda), Enfortumab Vedotin (Padcev), Sacituzumab Govitecan (Trodelvy)), Radiation Therapy, Targeted Therapy (Erdafitinib (Balversa)))
  4. By End-User (Hospitals, Specialty Cancer Centers, Others (Ambulatory Surgery Centers, etc.))
  5. By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific)
  6. By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia)